Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 29, 2015 12:58 PM ET

Biotechnology

Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...

3033 Science Park Road

Suite 300

San Diego, CA 92121

United States

Founded in 2008

68 Employees

Phone:

858-652-5700

Fax:

858-587-2659

Key Executives for Receptos, Inc.

Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $451.6K
Chief Financial Officer and Principal Accounting Officer
Age: 44
Total Annual Compensation: $254.8K
Chief Medical officer
Age: 44
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.

Receptos, Inc. Key Developments

Receptos, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM

Receptos, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States.

Receptos, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Receptos, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $37,159,000 against $15,099,000 a year ago. Net loss attributable to common stockholders was $38,151,000 or $1.32 per basic and diluted share against $15,244,000 or $0.86 per basic and diluted share a year ago. For the full year, the company reported loss from operations of $111,570,000 against $47,893,000 a year ago. Net loss attributable to common stockholders was $114,970,000 or $4.63 per basic and diluted share against $50,376,000 or $4.23 per basic and diluted share a year ago. Collaborative revenue was $5,900,000 against $4,641,000 a year ago.

Receptos, Inc. to Report Q4, 2014 Results on Mar 03, 2015

Receptos, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 03, 2015

Similar Private Companies By Industry

Company Name Region
Neogenix Oncology, Inc. United States
Nano Defense Solutions, Inc. United States
Existence Genetics, LLC United States
Scigenics, Inc. United States
Celexion, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Receptos, Inc., please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.